Addex Therapeutics Ltd (0QNV.L)

0,0647 -0,1923 (-74,82%) Alla chiusura: 06:59PM BST

Addex Therapeutics Ltd

Chemin des Mines, 9
Geneva 1202
Switzerland
41 22 884 1555
https://www.addextherapeutics.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 23

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Timothy Mark Dyer	Co-Founder, CEO & Director	N/D	N/D	1968
Dr. Roger G. Mills M.D.	Chief Medical Officer & Director	N/D	N/D	1957
Mr. Lénaic Teyssédou	Head of Finance	N/D	N/D	1986
Dr. Mikhail Kalinichev Ph.D.	Head of Translational Science	N/D	N/D	1967

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Addex Therapeutics Ltd al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.